Epratuzumab is a humanised monoclonal antibody targeting CD22 and modulating B-cell activity.
The data supported the BILAG-based Combined Lupus Assessment (BICLA) as a clinically meaningful composite measure of systemic lupus erythematosus (SLE) disease activity.
The British Isles Lupus Assessment Group (BILAG) index is a comprehensive, validated tool for assessing lupus disease activity.
In the EMBLEM study, all epratuzumab doses, ranging from 200mg to 3600mg dose administered during one 12-week treatment cycle had numerically superior BICLA response rates compared to placebo at week 12.